catalyst
pharmaceuticals
hold
third
quarter
financial
results
corporate
update
conference
call
webcast
tuesday
november
coral
gables
globe
newswire
catalyst
pharmaceuticals
catalyst
nasdaq
cprx
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
people
rare
debilitating
chronic
neuromuscular
neurological
diseases
today
announced
release
third
quarter
financial
results
market
close
monday
november
catalyst
management
host
conference
call
et
tuesday
november
discuss
financial
results
provide
corporate
update
investors
wish
participate
conference
call
may
dialing
domestic
canadian
callers
international
callers
interested
listening
conference
call
live
via
internet
may
visiting
investors
page
company
website
clicking
webcast
link
investors
home
page
webcast
replay
available
catalyst
website
days
following
call
visiting
investor
page
company
website
catalyst
pharmaceuticals
catalyst
pharmaceuticals
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
people
rare
debilitating
chronic
neuromuscular
neurological
diseases
including
myasthenic
syndrome
lems
antibody
positive
myasthenia
gravis
spinal
muscular
atrophy
sma
type
catalyst
new
drug
application
amifampridine
mg
tablets
treatment
adults
lems
approved
november
food
drug
administration
fda
commercially
available
united
states
canada
national
healthcare
regulatory
agency
health
canada
recently
approved
use
amifampridine
treatment
patients
canada
lems
currently
evaluated
clinical
trials
treatment
sma
type
received
orphan
drug
designation
fda
myasthenia
gravis
statements
press
release
contains
statements
statements
involve
known
unknown
risks
uncertainties
may
cause
catalyst
actual
results
future
periods
differ
materially
forecasted
results
number
factors
including
factors
described
catalyst
annual
report
form
fiscal
year
filings
securities
exchange
commission
sec
could
adversely
affect
catalyst
copies
catalyst
filings
sec
available
sec
may
found
catalyst
website
may
obtained
upon
request
catalyst
catalyst
undertake
obligation
update
information
contained
herein
speaks
date
investor
contact
brian
korb
solebury
trout
company
contact
patrick
mcenany
catalyst
pharmaceuticals
chief
executive
officer
media
contact
david
schull
russo
partners
